RecruitingPhase 2NCT07488117
Is [18F]-DPA-714 PET a Good Marker of Neuroinflammation in Autoimmune Encephalitis?
Sponsor
University Hospital, Toulouse
Enrollment
40 participants
Start Date
Mar 31, 2026
Study Type
INTERVENTIONAL
Conditions
Summary
This study aims to evaluate the effectiveness of \[18F\]-DPA-714 PET imaging in detecting neuroimmune activity in patients with autoimmune encephalitis (AE). The primary objective is to compare \[18F\]-DPA-714 binding in AE patients to healthy controls.
Eligibility
Min Age: 18 YearsMax Age: 80 Years
Inclusion Criteria5
- Age 18-80 years;
- meeting clinical criteria for "possible" AE with identified antibodies;
- newly diagnosed with symptoms <6 months;
- no second-line immunosuppressive treatment;
- high or mixed TSPO binding affinity phenotype.
Exclusion Criteria4
- Pregnant women;
- contraindications to MRI;
- known allergic reaction to \[18F\]-DPA-714; legal protection measure;
- paraneoplastic syndrome following immune checkpoint inhibitor therapy.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
OTHERTEP with radioligand EAI 714
60-minutes \[18F\]-DPA-714 PET imaging
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07488117